Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
32.32
+3.29 (11.33%)
Aug 19, 2026, 4:00 PM EDT - Market closed
Castle Biosciences Revenue
Castle Biosciences had revenue of $103.55M in the quarter ending June 30, 2026, with 20.14% growth. This brings the company's revenue in the last twelve months to $357.28M, up 3.18% year-over-year. In the year 2025, Castle Biosciences had annual revenue of $344.23M with 3.66% growth.
Revenue (ttm)
$357.28M
Revenue Growth
+3.18%
P/S Ratio
2.71
Revenue / Employee
$356,565
Employees
1,002
Market Cap
987.36M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 344.23M | 12.16M | 3.66% |
| Dec 31, 2024 | 332.07M | 112.28M | 51.09% |
| Dec 31, 2023 | 219.79M | 82.75M | 60.38% |
| Dec 31, 2022 | 137.04M | 42.95M | 45.65% |
| Dec 31, 2021 | 94.09M | 31.44M | 50.18% |
| Dec 31, 2020 | 62.65M | 10.78M | 20.79% |
| Dec 31, 2019 | 51.87M | 29.08M | 127.62% |
| Dec 31, 2018 | 22.79M | 9.03M | 65.67% |
| Dec 31, 2017 | 13.75M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 806.60M |
| NeoGenomics | 766.30M |
| OPKO Health | 587.90M |
| Veracyte | 561.90M |
| CareDx | 458.09M |
| GeneDx Holdings | 454.43M |
| Fulgent Genetics | 323.93M |
| GRAIL | 165.26M |
CSTL News
- 2 days ago - Castle Biosciences approved for dual listing on Nasdaq Texas - TheFly
- 2 days ago - Castle Biosciences Approved for Dual Listing on Nasdaq Texas - PRNewsWire
- 7 days ago - Castle Biosciences Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 15 days ago - Castle Biosciences price target raised to $44 from $40 at BTIG - TheFly
- 16 days ago - Castle Biosciences price target raised to $44 from $40 at BTIG - TheFly
- 19 days ago - Castle Biosciences price target raised to $57 from $52 at Lake Street - TheFly
- 19 days ago - Castle Biosciences price target lowered to $36 from $43 at Baird - TheFly
- 20 days ago - Castle Biosciences Earnings Call Transcript: Q2 2026 - Transcripts